Brought to you by 
TheraSense completes IPO the second time around
11 Feb 2002
Executive Summary
After filing and then withdrawing from an initial public offering last October, TheraSense (blood glucose monitoring devices) has netted $120.7mm with the sale of 6.9mm common shares (including the overallotment). It raised almost $20mm more than it originally expected.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Glucose Testing
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TheraSense completes IPO the second time around
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice